Editorial Peptide-Based Immunotherapeutics and Vaccines

Human Vaccines & Immunotherapeutics awards Top Reviewer of the Year

In its 9th year of publication Human Vaccines & Immunotherapeutics (HV&I) has become well-established in the vaccine community as an important forum for academics, companies, governmental and non-governmental organizations in this field. Our journal contains a mix of highquality original research and solicited content including timely reviews, commentaries, news, portraits, and much more. Its u...

Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications.

United Biomedical, Inc. (UBI) has developed a set of core technologies for the discovery and production of synthetic peptide-based immunotherapeutics and vaccines. These core technologies have led to products that stimulate functional site-directed antibody responses for therapeutic effects. UBI active immunotherapies can be used to modulate physiological processes effective for the control of ...

Peptide vaccines for hepatocellular carcinoma

Immunotherapy is a potentially attractive treatment option for patients with hepatocellular carcinoma (HCC). We have reported that glypican-3 (GPC3) is an ideal target for anticancer immunotherapy against HCC because its expression is specifically detected in > 80% of HCCs, even during the early stages. Further, increased GPC3 expression is correlated with a poor prognosis. Based on results obt...

Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.

Vaccine development for Group A streptococcal (GAS) infection has been extensively focused on the N-terminal hypervariable or the C-terminal conserved regions of the M protein, a major virulence factor of GAS. We evaluated the immunogenicity and functional activity of the conserved C-terminal peptide vaccine candidate, J8, conjugated to CRM197, in two mouse strains: C3H (H2(k)) and Balb/c (H2(d...

TILT Biotherapeutics.